RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1742927 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.20M | $1.39M | $1.44M | $1.74M | $2.13M | $3.72M | $4.11M | $4.68M |
| SG&A expense | $1.23M | $1.22M | $1.84M | $1.82M | $1.90M | $2.35M | $2.42M | $1.60M |
| Operating income | -$2.43M | -$2.62M | -$3.27M | -$3.56M | -$4.03M | -$6.07M | -$6.54M | -$6.28M |
| Interest expense | $1,174 | $2,935 | $6,653 | -$5,620 | $2,605 | $4,797 | $11,620 | $4,711 |
| Pretax income | -$2.30M | -$2.45M | -$3.19M | -$3.36M | -$4.01M | -$6.05M | -$6.43M | -$6.25M |
| Income tax | $1,934 | $2,632 | $3,346 | $2,882 | $2,840 | $7,954 | $5,213 | $4,733 |
| Net income | -$2.30M | -$2.45M | -$3.20M | -$3.37M | -$4.01M | -$6.05M | -$6.43M | -$6.26M |
| EPS (basic) | -0.17 | -0.19 | -0.46 | — | -1.09 | -2.40 | -2.61 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $17.46M | $19.89M | $22.19M | $14.44M | $13.18M | $10.36M | $5.29M | $13.48M |
| Current assets | $18.56M | $21.14M | $23.56M | $15.10M | $13.51M | $10.82M | $6.26M | $14.68M |
| Total assets | $18.56M | $21.14M | $23.56M | $15.92M | $14.33M | $11.63M | $7.08M | $15.50M |
| Current liabilities | $5.48M | $5.93M | $6.12M | $7.28M | $9.74M | $12.08M | $11.51M | $14.60M |
| Short-term debt | $44,388 | $144,093 | $231,274 | $406,875 | $0 | $113,246 | $224,300 | $458,154 |
| Total liabilities | $5.48M | $5.93M | $6.12M | $7.28M | $9.78M | $12.09M | $11.54M | $14.69M |
| Shareholders' equity | $13.08M | $15.21M | $17.44M | $8.65M | $4.55M | -$459,147 | -$4.46M | $812,572 |
| Shares outstanding | 13.11M | 13.11M | 12.81M | 5.87M | 96.34M | 68.00M | 46.74M | 2.36M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.18M | -$2.12M | -$3.80M | -$5.80M | -$5.59M | -$5.01M | -$8.19M | -$9.10M |
| Financing cash flow | -$247,189 | -$184,869 | $11.55M | $7.05M | $8.41M | $10.09M | $7,271 | $17.02M |
| Stock-based compensation | $171,021 | $214,565 | $584,439 | $455,084 | $458,379 | $395,277 | $919,119 | $554,216 |
Free plan shows the latest 8 periods; Pro shows all 37 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.